Switzerland
· Delayed Price · Currency is CHF Kuros Biosciences AG Statistics
Total Valuation
Kuros Biosciences AG has a market cap or net worth of CHF 633.39 million. The enterprise value is 621.08 million.
| Market Cap | 633.39M |
| Enterprise Value | 621.08M |
Important Dates
The next estimated earnings date is Thursday, November 7, 2024.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Kuros Biosciences AG has 37.30 million shares outstanding. The number of shares has increased by 0.34% in one year.
| Shares Outstanding | 37.30M |
| Shares Change (YoY) | +0.34% |
| Shares Change (QoQ) | +2.17% |
| Owned by Insiders (%) | 24.20% |
| Owned by Institutions (%) | 11.87% |
| Float | 25.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.40 |
| PB Ratio | 5.95 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -69.89 |
| EV / Sales | 11.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -191.28 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 3.26.
| Current Ratio | 2.73 |
| Quick Ratio | 2.08 |
| Debt / Equity | 3.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.60 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.32% and return on invested capital (ROIC) is -4.54%.
| Return on Equity (ROE) | -14.32% |
| Return on Assets (ROA) | -3.77% |
| Return on Capital (ROIC) | -4.54% |
| Revenue Per Employee | 495,679 |
| Profits Per Employee | -83,830 |
| Employee Count | 106 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +767.02% in the last 52 weeks. The beta is 0.86, so Kuros Biosciences AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | +767.02% |
| 50-Day Moving Average | 13.20 |
| 200-Day Moving Average | 7.93 |
| Relative Strength Index (RSI) | 71.46 |
| Average Volume (20 Days) | 287,654 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kuros Biosciences AG had revenue of CHF 52.54 million and -8.89 million in losses. Loss per share was -0.31.
| Revenue | 52.54M |
| Gross Profit | 46.11M |
| Operating Income | -4.69M |
| Pretax Income | -7.37M |
| Net Income | -8.89M |
| EBITDA | -3.05M |
| EBIT | -4.69M |
| Loss Per Share | -0.31 |
Balance Sheet
The company has 14.28 million in cash and 1.96 million in debt, giving a net cash position of 12.31 million or 0.33 per share.
| Cash & Cash Equivalents | 14.28M |
| Total Debt | 1.96M |
| Net Cash | 12.31M |
| Net Cash Per Share | 0.33 |
| Equity (Book Value) | 60.18M |
| Book Value Per Share | 2.85 |
| Working Capital | 21.08M |
Cash Flow
In the last 12 months, operating cash flow was -2.42 million and capital expenditures -832,000, giving a free cash flow of -3.25 million.
| Operating Cash Flow | -2.42M |
| Capital Expenditures | -832,000 |
| Free Cash Flow | -3.25M |
| FCF Per Share | -0.09 |
Margins
Gross margin is 87.77%, with operating and profit margins of -8.92% and -16.91%.
| Gross Margin | 87.77% |
| Operating Margin | -8.92% |
| Pretax Margin | -14.03% |
| Profit Margin | -16.91% |
| EBITDA Margin | -5.80% |
| EBIT Margin | -8.92% |
| FCF Margin | -6.18% |
Dividends & Yields
Kuros Biosciences AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.34% |
| Shareholder Yield | -0.34% |
| Earnings Yield | -1.83% |
| FCF Yield | -0.51% |
Stock Splits
The last stock split was on June 23, 2016. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jun 23, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.01 |